Oxford BioDynamics Plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OXBOF research report →
Price Chart
About the company
Oxford BioDynamics Plc operates as a biotechnology firm that specializes in identifying and advancing biomarkers, primarily for the pharmaceutical and biotechnology sectors across global markets, including the United States. Its flagship offering is EpiSwitch, an exclusive technological platform employed for discovering, assessing, validating, and tracking epigenetic biomarkers, specifically referred to as chromosome conformation signatures. These are crucial for developing medical diagnostic kits, predicting disease onset, aiding in diagnosis, and informing therapeutic strategies.
- CEO
- Richard Compton
- IPO
- 2020
- Employees
- 51
- HQ
- Oxford, OXF, GB
Get TickerSpark's AI analysis on OXBOF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.39M
- P/E
- -0.26
- PEG
- -0.00
- P/S
- 1.87
- P/B
- 1.23
- EV/EBITDA
- -0.45
- Div Yield
- 0.00%
- Gross Margin
- -277.32%
- Op Margin
- -792.72%
- Net Margin
- -825.61%
- ROE
- -451.74%
- ROIC
- -114.20%
Latest fiscal year · YoY change
- Revenue
- $1.09M+72.2%
- Gross Profit
- $522.00K+80.6%
- Op Income
- $-11,074,000
- Net Income
- $-11,153,000+3.6%
- EPS
- $-0.01+82.2%
- OCF Growth
- +25.6%
- FCF Growth
- +27.4%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.15
- RSI (14)
- 87
- Avg Volume
- 12.04K
No earnings-call transcripts are available for OXBOF yet.
- Free Float
- 65.0%
- Shares Outstanding
- 2.13B
- Float Shares
- 1.39B
Our OXBOF coverage
Recent articles, reports, and earnings notes.
No research on OXBOF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OXBOF report →Oxford BioDynamics shares soar 33% after unveiling breakthrough blood test for Chronic Fatigue Syndrome
proactiveinvestors.co.uk · Oct 8
Oxford BioDynamics unveils blood test for Chronic Fatigue Syndrome with 96% accuracy
proactiveinvestors.co.uk · Oct 8
Oxford BioDynamics shares climb blood test findings
proactiveinvestors.co.uk · Sep 4
Oxford BioDynamics partners with Google Cloud - ICYMI
proactiveinvestors.co.uk · Aug 22
Oxford BioDynamics soars on new Google collab
proactiveinvestors.co.uk · Aug 13
Oxford BioDynamics shares jump 66% after Pfizer validates blood-based cancer biomarker technology
proactiveinvestors.co.uk · Jul 15
Oxford BioDynamics shares jump on UK lab accreditation for flagship cancer test
proactiveinvestors.co.uk · May 9
Oxford BioDynamics slumps on warning of need for new funding
proactiveinvestors.co.uk · Oct 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.